Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3F8 |
Molecular Weight | 188.0193 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C(F)(F)C(F)(F)F
InChI
InChIKey=QYSGYZVSCZSLHT-UHFFFAOYSA-N
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11
Molecular Formula | C3F8 |
Molecular Weight | 188.0193 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Perflutren is a diagnostic drug that is used for the contrast enhancement during echocardiographic. It consists of lipid-coated microspheres filled with octafluoropropane gas. Ultrasound waves make the microspheres resonate and reflect a strong signal to an ultrasound machine. This results in a difference of density between gas-filled bubbles and blood around them and improves contrast of resulting images. Perflutren is used in patients with suboptimal echocardiograms to opacify the left ventricular chamber and improve the delineation of the heart borders.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DEFINITY Approved UseDEFINITY is an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. Launch Date2001 |
Doses
Dose | Population | Adverse events |
---|---|---|
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Disc. AE: Urticaria, Pruritus... AEs leading to discontinuation/dose reduction: Urticaria Sources: Page: p.6Pruritus Dizziness Chest pain Dyspnea Back pain |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1 |
Disc. AE: Anaphylactoid reaction... AEs leading to discontinuation/dose reduction: Anaphylactoid reaction (serious) Sources: Page: p.1 |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Disc. AE: Cardiac arrest, Respiratory arrest... AEs leading to discontinuation/dose reduction: Cardiac arrest (grade 5) Sources: Page: p.1, 5Respiratory arrest (grade 5) Shock (serious) Syncope (serious) Arrhythmia (serious) Hypertension (serious) Hypotension (serious) Dyspnea (serious) Hypoxia (serious) Chest pain (serious) Respiratory distress (serious) Stridor (serious) Wheezing (serious) Loss of consciousness (serious) Convulsions (serious) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Back pain | Disc. AE | 10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Chest pain | Disc. AE | 10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Dizziness | Disc. AE | 10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Dyspnea | Disc. AE | 10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Pruritus | Disc. AE | 10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Urticaria | Disc. AE | 10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.6 |
unhealthy, 18 - 93 n = 1716 Health Status: unhealthy Condition: Coronary artery disease Age Group: 18 - 93 Sex: M+F Population Size: 1716 Sources: Page: p.6 |
Anaphylactoid reaction | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1 |
Cardiac arrest | grade 5 Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Respiratory arrest | grade 5 Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Arrhythmia | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Chest pain | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Convulsions | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Dyspnea | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Hypertension | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Hypotension | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Hypoxia | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Loss of consciousness | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Respiratory distress | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Shock | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Stridor | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Syncope | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
Wheezing | serious Disc. AE |
10 uL/kg 1 times / 30 min multiple, intravenous Recommended Dose: 10 uL/kg, 1 times / 30 min Route: intravenous Route: multiple Dose: 10 uL/kg, 1 times / 30 min Sources: Page: p.1, 5 |
unhealthy Health Status: unhealthy Condition: Coronary artery disease Sources: Page: p.1, 5 |
PubMed
Title | Date | PubMed |
---|---|---|
Chromatic contrast thresholds as a prognostic test for visual improvement after macular hole surgery: color vision and macular hole surgery outcome. | 2001 |
|
Retinal detachment after pneumatic displacement for subfoveal hemorrhage. | 2001 |
|
Prostate cancer: contrast-enhanced us for detection. | 2001 Apr |
|
Recurrences of retinal detachment after vitreoretinal surgery, and surgical approach. | 2001 Apr-Jun |
|
Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement. | 2001 Jan |
|
Definity Health shifts risk all the way to the patient; employers attracted to 'new consumerism'. | 2001 Jul |
|
Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange. | 2001 May-Jun |
|
[Vitreoretinal surgery with intraocular C3F8 tamponade for retinal detachment due to macular hole without face-down positioning]. | 2001 Nov |
|
The impact of emission power on the destruction of echo contrast agents and on the origin of tissue harmonic signals using power pulse-inversion imaging. | 2001 Nov |
|
Directed biopsy during contrast-enhanced sonography of the prostate. | 2002 Apr |
|
Management of glaucoma after retinal detachment surgery. | 2002 Apr |
|
Bioeffects of myocardial contrast microbubble destruction by echocardiography. | 2002 Aug |
|
Effects of Optison on pulmonary gas exchange and hemodynamics. | 2002 Aug |
|
Vitreous surgery in highly myopic retinal detachment resulting from a macular hole. | 2002 Aug |
|
Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. | 2002 Dec |
|
Contrast enhanced duplex ultrasound imaging of the mesenteric arteries. | 2002 Jan |
|
Shortening the duration of prone positioning after macular hole surgery- comparison between 1-week and 1-day prone positioning. | 2002 Jan-Feb |
|
Visualization of uveal perfusion by contrast-enhanced harmonic ultrasonography at a low mechanical index: a pilot animal study. | 2002 Mar |
|
Seeking consensus: contrast ultrasound in radiology. | 2002 Mar |
|
A cost-utility analysis of interventions for severe proliferative vitreoretinopathy. | 2002 Mar |
|
Contrast material-enhanced abdominal US examinations with DMP 115 (DEFINITY) provides additional diagnostic information with potential for changes in patient management. | 2002 May |
|
Microvascular rheology of Definity microbubbles after intra-arterial and intravenous administration. | 2002 May |
|
Angle closure glaucoma following pupillary block in an aphakic perfluoropropane gas-filled eye. | 2002 Sep |
|
Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. | 2002 Sep |
|
Nitrous oxide anaesthesia in the presence of intraocular gas can cause irreversible blindness. | 2002 Sep 7 |
|
Lower receiving frequencies than transmitting frequencies could yield improved results for contrast imaging: an in vivo study in closed chest canines. | 2003 Apr |
|
Inverted pneumatic retinopexy. | 2003 Nov |
|
Early macular holes with retinoschisis in highly myopic eyes. | 2003 Oct |
|
Comparison of scleral buckling with combined scleral buckling and pars plana vitrectomy in the management of rhegmatogenous retinal detachment with unseen retinal breaks. | 2003 Oct |
|
Better success of retinal reattachment with long-standing gas tamponade in highly myopic eyes. | 2003 Oct |
|
Extra-low acoustic power harmonic images of the liver with perflutren: novel imaging for real-time observation of liver perfusion. | 2003 Sep |
|
Comparison of intravenous myocardial contrast echocardiography and low-dose dobutamine echocardiography for predicting left ventricular functional recovery following acute myocardial infarction. | 2003 Sep 1 |
|
Real-time assessment of myocardial perfusion during balloon angioplasty of the left anterior descending coronary artery. | 2003 Sep 15 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:35:37 GMT 2023
by
admin
on
Fri Dec 15 16:35:37 GMT 2023
|
Record UNII |
CK0N3WH0SR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
LUMINITY (AUTHORIZED: ECHOCARDIOGRAPHY)
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
||
|
NDF-RT |
N0000175864
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
OPTISON (AUTHORIZED: ECHOCARDIOGRAPHY)
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
||
|
NDF-RT |
N0000010259
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C47664
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
Perflutren
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
100000090070
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
31980
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
C418027
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
7932
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
8074
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
OCTAFLUOROPROPANE
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
283753
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
CK0N3WH0SR
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1663
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
CK0N3WH0SR
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
6432
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
C042852
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
2104
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
76-19-7
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
200-941-9
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
DB00556
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
SUB20657
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | |||
|
m8543
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID9052503
Created by
admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|